TABLE 3.
Demographic and clinical features of the two groups 1 year after the diagnosis; patients in EIM (+) group have extraintestinal manifestations with intestinal symptoms and patients in EIM (−) group only express intestinal symptoms.
| EIM (+) group (N = 47) |
EIM (−) group (N = 95) |
P-value | ||
| PUCAIa | 13.80 ± 16.94 | 13.05 ± 12.95 | 0.791c | |
| Hematocrit, g/dl | 38.22 ± 5.17 | 40.07 ± 3.84 | 0.019c | |
| Albumin, g/dl | 5.14 ± 0.42 | 4.46 ± 0.37 | 0.223c | |
| ESR, mm/h | 30.72 ± 28.73 | 18.25 ± 16.07 | 0.001c | |
| CRP, mg/dl | 0.52 ± 0.95 | 0.22 ± 0.45 | 0.011c | |
| Disease extent of Paris classification | ||||
| None | 7 (14.9) | 32 (33.7) | 0.001d | |
| E1 | Proctitis | 11 (23.4) | 28 (29.5) | |
| E2 | Left colitis | 6 (12.8) | 11 (11.6) | |
| E3 | Extensive colitis | 11 (23.4) | 15 (15.8) | |
| E4 | Pancolitis | 12 (25.5) | 9 (9.5) | |
| Mayo endoscopic subscoreb | 0.005d | |||
| 0 | Normal or inactive | 10 (21.3) | 33 (34.7) | |
| 1 | Mild | 15 (31.9) | 41 (43.2) | |
| 2 | Moderate | 19 (40.4) | 20 (21.1) | |
| 3 | Severe | 3 (6.4) | 1 (1.1) | |
| Systemic corticosteroid | 25 (53.2) | 29 (30.5) | 0.009d | |
| Immunosuppressants | 43 (91.5) | 62 (65.3) | 0.001d | |
| Biologic agents | 31 (66.0) | 28 (29.5) | <0.001d | |
| EIM improvement | ||||
| Yes | 44 (93.6) | |||
| No | 3 (6.4) | |||
EIM, Extraintestinal manifestation; N, number of patients.
Values are represented in “n (percentage)” or “average ± standard deviation.”
aPediatric Ulcerative Colitis Activity Index (PUCAI) is a 6-item disease activity index intended for use in pediatric UC clinical trials with a score ranging from 0 – 85.
bMayo endoscopy subscores were as follows: 0, normal or inactive disease; 1, mild disease; 2, moderate disease; and 3, severe disease.
cStudent t-test.
dχ2 test. Bold values mean statistically significant values with p-value < 0.05.